Genmab has decided to let the royalties dispute over multiple myeloma treatment Darzalex with its collaboration partner Janssen lie.
In connection with firm’s first quarterly report for 2022, which was released on Wednesday, Genmab reports that it will not seek a review of the ruling, making the arbitration award final.
More from MedWatch
In 2015, Genmab partnered with relatively unknown biotech firm Biontech. Reflecting on how far Genmab has come since, CEO Jan van de Winkel is still confident that partnerships, rather than acquisitions, are the way forward. If it had acquired Biontech at the time, the CEO speculates Genmab may have put a stop to other activities – including the Covid-19 vaccine efforts that went on to save millions of lives. This and fairness are worth remembering as biotech firms are increasingly strapped for cash, van de Winkel reflects.